Cannara Historical Income Statement
| LOVE Stock | CAD 0.70 0.02 2.78% |
Historical analysis of Cannara Biotech income statement accounts such as Selling General Administrative of 9.7 M can show how well Cannara Biotech performed in making a profits. Evaluating Cannara Biotech income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Cannara Biotech's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Cannara Biotech latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cannara Biotech is a good buy for the upcoming year.
Cannara |
About Cannara Income Statement Analysis
Cannara Biotech Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Cannara Biotech shareholders. The income statement also shows Cannara investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Cannara Biotech Income Statement Chart
Add Fundamental
Tax Provision
The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.Net Interest Income
The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.Interest Expense
The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.Most accounts from Cannara Biotech's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Cannara Biotech current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Cannara Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. At this time, Cannara Biotech's Reconciled Depreciation is fairly stable compared to the past year. Income Before Tax is likely to climb to about 8.4 M in 2024, whereas Interest Income is likely to drop slightly above 181 K in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 17.3M | 27.2M | 31.3M | 32.9M | Total Revenue | 35.8M | 57.3M | 65.8M | 69.1M |
Cannara Biotech income statement Correlations
Click cells to compare fundamentals
Cannara Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cannara Biotech income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Interest Income | (1.1M) | (1.7M) | (3.2M) | (5.0M) | (4.5M) | (4.3M) | |
| Interest Income | 265.8K | 52.8K | 92.7K | 239.5K | 215.6K | 181.0K | |
| Interest Expense | 1.3M | 1.6M | 1.9M | 3.9M | 4.5M | 4.7M | |
| Selling General Administrative | 9.0M | 7.3M | 10.0M | 13.5M | 15.5M | 9.7M | |
| Total Revenue | 2.5M | 16.3M | 35.8M | 57.3M | 65.8M | 69.1M | |
| Gross Profit | 1.1M | 9.6M | 17.3M | 27.2M | 31.3M | 32.9M | |
| Operating Income | (11.9M) | 299.2K | 5.0M | 12.0M | 13.8M | 14.5M | |
| Net Income From Continuing Ops | (13.1M) | (1.5M) | 2.3M | 6.9M | 8.0M | 8.4M | |
| Ebit | (9.9M) | (12.0M) | 52.6K | 4.8M | 5.5M | 5.8M | |
| Ebitda | (10.9M) | (9.2M) | 3.1M | 8.1M | 9.4M | 9.8M | |
| Cost Of Revenue | 1.3M | 6.7M | 18.5M | 30.0M | 34.5M | 36.3M | |
| Total Operating Expenses | 14.4M | 16.0M | 30.9M | 45.2M | 52.0M | 54.6M | |
| Reconciled Depreciation | 2.6M | 3.0M | 3.9M | 4.9M | 5.7M | 6.0M | |
| Income Before Tax | (13.1M) | (1.5M) | 2.3M | 6.9M | 8.0M | 8.4M | |
| Net Income Applicable To Common Shares | (12.3M) | (12.5M) | (1.5M) | 2.3M | 2.7M | 2.8M | |
| Net Income | (12.5M) | (1.5M) | 2.3M | 6.9M | 8.0M | 8.4M | |
| Total Other Income Expense Net | (67.3K) | (154.5K) | 551.4K | (68.0K) | (78.2K) | (82.1K) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cannara Stock Analysis
When running Cannara Biotech's price analysis, check to measure Cannara Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannara Biotech is operating at the current time. Most of Cannara Biotech's value examination focuses on studying past and present price action to predict the probability of Cannara Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannara Biotech's price. Additionally, you may evaluate how the addition of Cannara Biotech to your portfolios can decrease your overall portfolio volatility.